Life Technologies Corp is up for sale and many important players in the industry are taking notice. These include Roche Holding AG and a consortium led by KKR & Co LP with Hellman and Friedman LLC. The company for sale is deep into genetic testing using advanced diagnostic technology.
Another aspect of Life Technologies that makes it very attractive is its steady cash flow and its US$11 billion market valuation, according to sources who requested anonymity. Roche's bid indicates the Swiss pharmaceutical's interest in genetic sequencing. In the previous year, Roche sought to acquire another genetic sequence firm Illumina Inc but failed due to price considerations.
Other firms in the mix include Thermo Fisher Scientific Inc, another buyout consortium of Blackstone Group LP, Carlyle Group LP, TPG Capital LP and Temasek Holdings of Singapore as well as Danaher Corp, according to a previous Reuters report. Bidding would end by April.
Join the Conversation